This inventor holds 1 USPTO granted patent. Top assignee: Natco Pharma Limited. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovative Journey of Gampa Venugopala Krishna
Introduction: Gampa Venugopala Krishna, an accomplished inventor based in Hyderabad, Telangana, India, has made significant contributions to the field of pharmaceutical sciences. With one patent to his name, he has showcased his innovative spirit and dedication to advancing medicine.
Latest Patents: Gampa's notable patent is titled "Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof." This invention pertains to an enhanced method for producing the compound N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, represented by a specific structural formula. His work in this patent addresses important aspects of pharmaceutical chemistry, aiming to improve the availability of this vital compound.
Career Highlights: Gampa Venugopala Krishna is currently associated with Natco Pharma Limited, a prominent player in the pharmaceutical industry. His role at the company allows him to harness his innovative ideas and contribute to the development of life-saving medications. The impact of his work can be felt throughout the healthcare sector, given the importance of the compounds he is developing.
Collaborations: Throughout his journey, Gampa has collaborated with talented professionals, including his coworkers Kompella Amala and Annadasu Ankamanayudu. Together, they foster a collaborative environment that encourages innovation and the sharing of ideas, enhancing their collective ability to bring new inventions to fruition.
Conclusion: Gampa Venugopala Krishna exemplifies the spirit of innovation in the pharmaceutical sector. His patent for the preparation of Cabozantinib not only highlights his ingenuity but also his commitment to improving healthcare outcomes. As he continues to work with Natco Pharma Limited and collaborate with fellow innovators, the future holds great promise for further advancements in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
